If you would like to ask our webinar guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund a question please submit them here.
RA Capital have kept their TechAtlas going on Covid 19.
https://www.racap.com/covid-19
Although it takes a bit of getting used to, imho it’s the most comprehensive collection of uptodate data on what’s happening therapeutically and diagnostically with the disease.
We’re still there, of course, therapeutics/ bottom left.
;-)
My understanding is that firms like Polar Capital invest on behalf of clients, whom they advise.
Therefore any change in PC’s holdings may be because of a client's instructions to buy some/sell some, based on the latter’s individual situation.
Polar’s advice may not have changed, but their client’s may need to adjust their finances.
Any comments welcome.
….in having to deal with suspicious UK government decision-making.
https://blogs.bmj.com/bmj/2021/07/11/why-all-the-secrecy-around-innova-lateral-flow-tests/
Tornadotony,
Since it’s so difficult to value Synairgen, are you able to suggest why 170p bid is such a point of resistance, as it seems to me to have no particular relevance (£340m)?
With a ‘busy’ non-news day producing about 1-2m traded volume, it looks like 198m/199m shares are effectively dormant.
Very spooky.
;-)
https://www.forbes.com/sites/roystonwild/2021/06/09/clinigen-groups-share-price-plummets-25-after-shock-profit-warning/?sh=48eef57858c9
May not have helped the MAP ?
Plenty on the Web about algorithmic trading.
https://www.investopedia.com/articles/active-trading/101014/basics-algorithmic-trading-concepts-and-examples.asp
Also watch ‘The Big Short’ where high frequency trading is taken to the limit to get an edge.
Very similar to a 2Code, 3Code, 4Code etc etc
To ‘people in the know’ they mean that there may be news -or there may not.
Can be very stressful not being ‘in the know’.
Now, a 500,000Code might actually mean something….
;-)
Surely volatility to be expected, as it’s largely guesswork as to Synairgen’s proper value.
We have no idea on the sale price of the drug; the cost of production, hence the profit per unit; the size of the relevant market/s and the cost of treatment; any suggestion of a joint venture partner; Synairgen’s capability (or not) to ‘go it alone’; and, of course, just how effective the drug is in the Phase 3.